GNNSF - GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
2024-03-20 07:15:00 ET
Summary
- GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction.
- Legend Biotech continues to invest in R&D to expand the number of indications that Carvykti can treat, with seven clinical studies now in progress.
- Legend’s Carvykti is expected to hit annual production capacity of 10,000 doses by the end of 2025.
The pharma company's losses narrowed 58% last year, as its life sciences and cell therapy businesses experienced strong growth ...
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy